CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 8 enrolled
Drug / intervention
[14C]-benzo[a]pyrene +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03631667
NCT03631667Early Ph 1Completed
CompareCT.gov

Ultralow Dose PAH Binary Mixture Study

Oregon State University·interventional·Posted Aug 15, 2018·Updated May 22, 2025

In Brief

A Early Phase 1 clinical trial evaluating [14C]-benzo[a]pyrene and [14C]-benzo[a]pyrene plus phenanthrene for Environmental Exposure. Completed, enrolled 8 participants across 1 site.

Detailed Summary

Evaluation of the pharmacokinetics for \[14C\]-benzo\[a\]pyrene (\[14C\]-BaP) and metabolites in plasma and urine over 48 hours following a 50 ng dose (5.4 nCi) alone or with 1250 ng phenanthrene.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEnvironmental Exposure
CountriesUnited States
CollaboratorsNational Institute of Environmental Health Sciences (NIEHS), Lawrence Livermore National Laboratory, Pacific Northwest National Laboratory

Timeline

Early Ph 1CompletedFinished
20192020202120222023202420252026
First PostedAug 15, 2018
Enrollment StartOct 1, 2018
Primary CompletionJan 1, 2024
Study CompletionFeb 1, 2024
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 7.9 years ago

Interventions

[14C]-benzo[a]pyrenedrug

Oral micro-dose (50 ng) (5.4 nCi)

[14C]-benzo[a]pyrene plus phenanthrenedrug

Oral micro-dose of 50 ng (5.4 nCi) \[14C\]-benzo\[a\]pyrene plus 1250 ng phenanthrene